Compare · STVN vs SYK
STVN vs SYK
Side-by-side comparison of Stevanato Group S.p.A. (STVN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STVN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $119.19B, about 27.4x STVN ($4.35B).
- SYK has been more active in the news (12 items in the past 4 weeks vs 10 for STVN).
- Both have 25 recent analyst ratings on file.
- Company
- Stevanato Group S.p.A.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $4.35B
- $119.19B
- 1M return
- -
- +5.35%
- 1Y return
- -
- -13.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 10
- 12
- Recent ratings
- 25
- 25
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest STVN
- Stevanato Group to Participate in Upcoming Investor Conferences
- Director Federici William J bought $274,400 worth of Ordinary Shares (20,000 units at $13.72), increasing direct ownership by 74% to 46,991 units (SEC Form 4)
- SEC Form 6-K filed by Stevanato Group S.p.A.
- Director Morel Donald E Jr bought $326,750 worth of Ordinary Shares (25,000 units at $13.07), increasing direct ownership by 67% to 62,424 units (SEC Form 4)
- Stevanato Group S.p.A. downgraded by William Blair
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
- Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Latest SYK
- Director Stryker Ronda E sold $178,924,731 worth of shares (550,000 units at $325.32) (SEC Form 4)
- Stryker Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Stryker announces intention to nominate Jim Davis to board of directors
- What 3.4% GDP Growth and a 4.2% Jobless Rate Say About a Hard Day on Wall Street
- SEC Form S-3ASR filed by Stryker Corporation
- SEC Form IRANNOTICE filed by Stryker Corporation
- SEC Form 10-Q filed by Stryker Corporation
- Stryker downgraded by Canaccord Genuity with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker reports third quarter 2026 operating results